title: Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease.
abstract: We performed a double-blind randomized placebo-controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS).
authors.affiliation: Parkinson's Disease and Movement Disorders Center, NPF Center of Excellence, University of South Florida, Tampa, Florida 33612, USA. kbarber@hsc.usf.edu
authors.forename: Kelly L
authors.initials: KL
authors.lastname: Sullivan
authors.forename: Joseph F
authors.initials: JF
authors.lastname: Staffetti
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hauser
authors.forename: Peter B
authors.initials: PB
authors.lastname: Dunne
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Zesiewicz
mesh_terms: D000368:Aged; D003248:Constipation / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D005769:Gastrointestinal Motility / Q000187:drug effects; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D017060:Patient Satisfaction; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage*
chemical_list: D005765:Gastrointestinal Agents; D007211:Indoles; D058828:Serotonin 5-HT4 Receptor Agonists; D017366:Serotonin Receptor Agonists; C105050:tegaserod